Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Av-101. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 3/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.40 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Av-101 SCHEMBL18742668 | 1.00 | KMO (0.51) | KMOHIF1AKDM4ETDP1ABL1 | |
| Av-101 SCHEMBL727370 | 1.00 | KMO (0.51) | KMOHIF1AKDM4ETDP1ABL1 | |
| Av-101 SCHEMBL30852264 | 1.00 | KMO (0.51) | KMOHIF1AKDM4ETDP1ABL1 | |
| Av-101 SCHEMBL30216614 | 1.00 | KMO (0.51) | KMOHIF1AKDM4ETDP1ABL1 | |
| Av-101 SCHEMBL30733184 | 1.00 | KMO (0.51) | KMOHIF1AKDM4ETDP1ABL1 | |
| Av-101 SCHEMBL16098317 | 0.93 | KMO (0.46) | KMOHIF1AKDM4ETDP1ABL1 | |
| SCHEMBL8397345 | 0.88 | KMO (0.51) | KMOHIF1AKDM4ETDP1GRIK1 | |
| SCHEMBL30852448 | 0.88 | KMO (0.51) | KMOHIF1AKDM4ETDP1GRIK1 | |
| SCHEMBL8397341 | 0.88 | KMO (0.51) | KMOHIF1AKDM4ETDP1GRIK1 | |
| SCHEMBL30852441 | 0.88 | KMO (0.51) | KMOHIF1AKDM4ETDP1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098007-A1 | Compounds and Their Use in Filtering Ultraviolet and/or High-Energy Visible Light | SOLIOME INC (US) | 2026-04-09 | — | — | US | claimed |
| WO-2025264860-A2 | METHODS OF TREATING POST-COVID AIRWAY DISEASE | YALE UNIVERSITY (US) | 2025-12-26 | — | — | WO | claimed |
| US-20250360208-A1 | USE OF GLUTAMATE MODULATING AGENTS WITH IMMUNOTHERAPIES TO TREAT CANCER | BIOHAVEN THERAPEUTICS LTD (US) | 2025-11-27 | — | — | US | claimed |
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2025-11-06 | — | — | US | claimed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250312293-A1 | ESKETAMINE FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER | CLEXIO BIOSCIENCES LTD (IL) | 2025-10-09 | — | — | US | claimed |
| EP-4608424-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS Therapeutics SAS (FR) | 2025-09-03 | — | — | EP | claimed |
| US-20250255792-A1 | Methods of Using a Small Molecule Chemical Compound to Reduce the Appearance of Rhytids and Wrinkles | BIRCHBIOMED INC. (CA) | 2025-08-14 | — | — | US | claimed |
| EP-4587007-A2 | COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT | Soliome, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | claimed |
| US-20220354827-A1 | NTRANASAL DANTROLENE ADMINISTRATION FOR TREATMENT OF ALZHEIMER'S DISEASE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-11-10 | — | — | US | claimed |
| US-20220290196-A1 | GENETICALLY ENGINEERED MICROBES AND BIOSYNTHETIC METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-09-15 | — | — | US | claimed |
| CN-114828848-A | Intranasal dantrolene administration for the treatment of alzheimer's disease | 宾夕法尼亚大学理事会 | 2022-07-29 | — | — | CN | claimed |
| US-20220202756-A1 | GENETIC VARIANTS ASSOCIATED WITH RESPONSE TO TREATMENT OF NEUROLOGICAL DISORDERS | VISTAGEN THERAPEUTICS INC (US) | 2022-06-30 | — | — | US | claimed |
| US-20220143041-A1 | COMBINED THERAPY FOR NMDAR ANTAGONIST-RESPONSIVE NEUROPSYCHIATRIC DISORDERS | GLYTECH LLC (US) | 2022-05-12 | — | — | US | claimed |
| US-20220127261-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | CERTEGO ABC, LLC | 2022-04-28 | — | — | US | claimed |
| EP-3952856-A1 | GENETIC VARIANTS ASSOCIATED WITH RESPONSE TO TREATMENT OF NEUROLOGICAL DISORDERS | Vistagen Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| CN-114007600-A | Genetic variation associated with therapeutic response to neurological disorders | 维斯塔津治疗公司 | 2022-02-01 | — | — | CN | claimed |
| EP-3197466-B1 | A COMBINATION OF KYNURENINE AND ANTIGEN PRESENTING CELLS (APC) AS THERAPEUTICS AND METHODS FOR THEIR USE IN IMMUNE MODULATION | UNIV BRITISH COLUMBIA (CA) | 2021-02-17 | — | — | EP | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | NLN, DCX, CNTN1 | KMO 2256/4885HIF1A 2245/4885KDM4E 4769/4885 |
| US-20250360208-A1 | USE OF GLUTAMATE MODULATING AGENTS WITH IMMUNOTHERAPIES TO TREAT CANCER | CD274, PDCD1LG2, GRM1 | KMO 880/4885HIF1A 2324/4885KDM4E 1018/4885 |
| US-20220127261-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | GABRD, GABRA6, GABRA3 | KMO 49/4885HIF1A 2578/4885KDM4E 354/4885 |
| US-20260098007-A1 | Compounds and Their Use in Filtering Ultraviolet and/or High-Energy Visible Light | UGT8, UGT1A3, FUT5 | KMO 2997/4885HIF1A 3431/4885KDM4E 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.